SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

Medigene AG. (4/16/15). "Press Release: Medigene to Participate in Three Upcoming International Conferences". Martinsried.

Organisations Organisation Medigene AG (FSE: MDG1, Prime Standard)
  Group Medigene (Group)
  Organisation 2 Kempen & Co. Corporate Finance
  Group Van Lanschot (Group)
Products Product DC vaccine (dentritic cell vaccine)
  Product 2 Kempen & Co Healthcare & Life Sciences Conference 2015 New York
Index term Index term Medigene–Van Lanschot: investor conference, 201504 supply service Medigene participant at Kempen & Co Healthcare + Life Sciences Conference in NY
Persons Person Schendel, Dolores J. (Medigene 201602– CEO before CMO before Trianta Immunotherapies + HelmholtzZentrum München)
  Person 2 Kvalheim, Gunnar (Univ Oslo 201504 Prof at Dept of Cellular Therapy at Oslo Univ Hospital)

Medigene AG (MDG1, Frankfurt, Prime Standard) announces its participation in three upcoming investment and scientific conferences:

8th Kempen & Co Healthcare & Life Sciences Conference

Date: 16 April 2015
Location: New York, USA

AACR Annual Meeting 2015

Date: 18 - 22 April 2015
Location: Philadelphia, USA
Medigene's academic partner, the Oslo University Hospital (Prof. Gunnar Kvalheim, Head of Department of Cellular Therapy) will present clinical data of its DC vaccine program.[1]
Presentation Time: Monday, 20 April 2015, 1:00 pm - 5:00 pm local time

3rd CIMT Endeavour Workshop

Date: 12 May 2015
Location: Mainz, Germany
Prof. Dolores J. Schendel, Chief Scientific Officer, Medigene AG will give a presentation titled "The long and short history of Trianta Immunotherapies: From virtual academic spin-out to subsidiary of Medigene AG"

Medigene AG is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company headquartered in Martinsried near Munich, Germany. Medigene concentrates on the development of personalized T cell immunotherapies with a focus on haematological malignancies. Medigene is the first German biotech company to have revenues from a marketed product, which is distributed by commercial partner companies. Medigene has advanced drug candidates which are licensed to partners and additional candidates in clinical development. The company is developing highly innovative treatment platforms concentrating on cancer and autoimmune diseases. For more information, please visit

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® EndoTAG® and Veregen® are registered trademarks of Medigene AG. These trademarks may be owned or licensed in select locations only.

Contact Medigene

Julia Hofmann, Anja Clausnitzer
Tel.: +49 - 89 - 20 00 33 - 33 01

[1] The Oslo University Hospital has an agreement with Medigene for use of Medigene`s new generation DC vaccines for their ongoing academic clinical studies.

Record changed: 2017-07-02


Picture [LSUS] – The Business Web Portal 600x60px

More documents for Medigene (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSG] – The Business Web Portal 600x80px

» top